Enzo Biochem Story

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;'>EB</div>
ENZ -- USA Stock  

USD 3.04  0.05  1.67%

With so much uncertainty about the healthcare space, it is fair to break down Enzo Biochem against current market trends. As we have suggested previously, Enzo Biochem is beginning its slide as investors shift to be more bearish due to the increased sector volatility. Enzo Biochem follows the market closely. The returns on the market and returns on Enzo Biochem appear slightly correlated for the last few months. Strong basic indicators of the company may suggest signs of short-term price drift for investors. Enzo Biochem is scheduled to announce its earnings tomorrow.
Published over three months ago
View all stories for Enzo Biochem | View All Stories
Is Enzo Biochem (NYSE:ENZ) moving to revert?
Enzo Biochem's average rating is Strong Buy from 1 analysts. Do analysts base this consensus on technical analyses? We know that typical technical analysis utilizes price momentum, patterns, and trends looking at historical prices. It aims to identify signals based on Enzo Biochem market sentiment investors' perception of the future value of Enzo Biochem. Let us look at a few aspects of Enzo Biochem technical analysis. The company has Net Profit Margin of (39.5) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (40.82) %, which entails that for every $100 of revenue, it lost -0.41.
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of Enzo Biochem. In general, we focus on analyzing Enzo Biochem stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Enzo Biochem's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of Enzo Biochem's intrinsic value. In addition to deriving basic predictive indicators for Enzo Biochem, we also check how macroeconomic factors affect Enzo Biochem price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research.
Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of Enzo Biochem's stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of Enzo Biochem in the context of predictive analytics.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Enzo Biochem. Your research has to be compared to or analyzed against Enzo Biochem's peers to derive any actionable benefits. When done correctly, Enzo Biochem's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in Enzo Biochem.

How does Enzo Biochem Stands against Peers?

Analyzing Enzo Biochem competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to Enzo Biochem across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be.
Check out Enzo Biochem Competition Details

How Enzo Biochem utilizes its cash?

To perform a cash flow analysis of Enzo Biochem, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Enzo Biochem is receiving and how much cash it distributes out in a given period. The Enzo Biochem cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Enzo Biochem Net Cash Flow from Operations is fairly stable at the moment as compared to the past year. Enzo Biochem reported Net Cash Flow from Operations of (19.76 Million) in 2020

Acquisition by Ian Walters of 77101 shares of Enzo Biochem subject to Rule 16b-3

Legal trades by Enzo Biochem insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Enzo Biochem insider trading alert for grant of stock option (to acquire common stock) by Ian Walters, the corporate stakeholder, on 13th of January 2021. This event was filed by Enzo Biochem Inc with SEC on 2021-01-13. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Breaking down Enzo Biochem Indicators

The entity has a beta of 0.7496. Let's try to break down what Enzo Biochem's beta means in this case. As returns on the market increase, Enzo Biochem returns are expected to increase less than the market. However, during the bear market, the loss on holding Enzo Biochem will be expected to be smaller as well. The beta indicator helps investors understand whether Enzo Biochem moves in the same direction as the rest of the market, and how volatile (i.e., risky) it is compared to the market (i.e., selected benchmark). In other words, if Enzo Biochem deviates very little from the market, it does not add much risk to the portfolio, but it also doesn't increase the expected returns. Enzo Biochem price slide over the last few months could raise concerns from investors as the firm it trading at a share price of 2.31 on very low momentum in volume. The company executives were not very successful in positioning the firm resources to exploit market volatility in September. However, diversifying your holdings with Enzo Biochem or similar stocks can still protect your portfolio during high-volatility market scenarios. The stock standard deviation of daily returns for 30 days investing horizon is currently 3.2. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Enzo Biochem partners.

Our take on Enzo Biochem small slide

Current Information Ratio is up to -0.1. Price may slide again. Enzo Biochem exhibits very low volatility with skewness of 0.15 and kurtosis of 0.12. However, we advise investors to further study Enzo Biochem technical indicators to make sure all market info is available and is reliable.

Our Bottom Line On Enzo Biochem

While some other entities in the diagnostics & research industry are either recovering or due for a correction, Enzo Biochem may not be as strong as the others in terms of longer-term growth potentials. On the whole, as of the 12th of October 2020, we believe that at this point, Enzo Biochem is undervalued with below average probability of financial unrest within the next 2 years. Our present buy-hold-sell recommendation on the company is Strong Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Ellen Johnson do not own shares of Enzo Biochem. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com